The collaboration will use GGI’s ML & AI innovations to direct individualized healthcare via the Curo46 engine & Moleculera’s expertise in autoimmune neuropsychiatric disorders along with patient data by using Moleculera Labs’ AE/BGE or Cunningham Panel
This blood test measures the levels of Abs that target the brain and CNS & are linked to neurologic, psychiatric & behavioral diseases. General Genomics uses a variety of data sources with its AI expertise to determine a person’s risk for illness, disease & the probability of treatment success, effective & free of side effects
This collaboration will give superior precision medicine tools for treating neuropsychiatric diseases, minimizing the need for trial and error
Ref: PRNewswire | Image: Moleculera Labs
